title: Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
abstract: OBJECTIVE
  The purpose of this study was to investigate the effect of stereotactic radiosurgery on local control and organ preservation in cases of primary head and neck cancer.
  
  
  METHODS
  In this retrospective study, 14 patients with a mean age of 73 years were treated between March 2006 and September 2007 with stereotactic radiosurgery for the management of primary head and neck cancer. The patients had biopsy confirmation of disease before treatment and all patients were confirmed with squamous cell carcinoma. The staging consisted of T2 (5 cases), T3 (3 cases), T4 (6 cases), N0 (13 cases), and N1 (1 case). Marginal doses were 3,500 to 4,200 cGy in 3 or 5 fractions. The outcome was assessed according to Response Evaluation Criteria in Solid Tumors criteria based on magnetic resonance imaging and positron emission tomography/computed tomography.
  
  
  RESULTS
  Significant tumor reduction was noted at the third month of follow-up with 5 complete responses and 9 partial responses. At a mean follow-up of 36 months (range, 14-40 mo) the local control and overall survival rates were 71.4% (10/14) and 78.6% (11/14), respectively.
  
  
  CONCLUSIONS
  These results show the feasibility of using stereotactic radiosurgery for primary head and neck cancer and its potential benefit in local control and organ preservation.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Tsurumi University, School of Dental Medicine, Tsurumi-ku, Yokohama, Japan. kawaguchi-k@tsurumi-u.ac.jp
authors.forename: Koji
authors.initials: K
authors.lastname: Kawaguchi
authors.forename: Kengo
authors.initials: K
authors.lastname: Sato
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yamada
authors.forename: Akihisa
authors.initials: A
authors.lastname: Horie
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Nomura
authors.forename: Susumu
authors.initials: S
authors.lastname: Iketani
authors.forename: Ikuyo
authors.initials: I
authors.lastname: Kanai
authors.forename: Satoshi
authors.initials: S
authors.lastname: Suzuki
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Nakatani
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Hamada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D008207:Lymphatic Metastasis / Q000175:diagnosis; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D010347:Patient Care Planning; D049268:Positron-Emission Tomography; D016634:Radiosurgery; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D005472:Fluorouracil